Search clinical trials for: integrase inhibitor

Total 68022 results

University of Washington
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Terminated

RESIST-2: 2nd-line ART for HIV-2 Infection (RESIST-2)

HIV-2 Infection

Senegal
National Jewish Health
Merck Sharp & Dohme LLC

Completed

Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen

HIV

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection

HIV Infections | Infection, Human Immunodeficiency Virus

Mexico, Peru, Thailand, South Africa, Russian Federation, Argentina, Brazil
Radboud University Medical Center

Completed

Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole Tablet (SCRUM)

HIV

Netherlands
Radboud University Medical Center

Terminated

Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen (PRADAII)

HIV-1 Infection

Netherlands, Germany
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir (OPAL)

HIV Infections | HCV Infections

Netherlands
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

The Influence of GINkGo Biloba on the Pharmacokinetics of the UGT Substrate raltEgraviR (GINGER) (GINGER)

Depression | HIV Infections | Mild Cognitive Impairment

Netherlands
Radboud University Medical Center

Completed

Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients (PRADA)

HIV Infections | HIV Infection

Germany, Netherlands
Kirby Institute
National Institute of Allergy and Infectious Diseases (NIAID); ViiV Healthcare and other collaborators

Withdrawn

Inflammation and Co-Infections in D²EFT (i2-D²EFT)

Cytomegalovirus Infections | Human Papilloma Virus | HIV-infection/Aids | Human Herpesvirus 4 Infections | Human Herpesvirus 8 Infection
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Completed

Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen

Aging-related Inflammation in HIV-infected Patients

Spain
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin. (AVIATOR)

HIV | Hypercholesterolaemia

Netherlands
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

The Influence of Raltegravir on Pravastatin Pharmacokinetics(GRAPPA) (GRAPPA)

HIV Infections

Netherlands
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen

HIV Infections

Spain, United States, Canada, Belgium, United Kingdom, Argentina
Radboud University Medical Center
Merck Sharp & Dohme LLC

Completed

Pharmacokinetic Study on Raltegravir and Lamotrigine (GRANOLA)

HIV Infection

Netherlands
Radboud University Medical Center

Completed

Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL). (RECITAL)

Depression | HIV

Netherlands
ViiV Healthcare
GlaxoSmithKline

Completed

Dolutegravir Expanded Access Study (DEAP)

HIV Infections | Infection, Human Immunodeficiency Virus

France, Germany, United States, Canada, Belgium, Austria, Brazil, Italy, Poland
ViiV Healthcare
GlaxoSmithKline

Completed

Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

HIV Infections | Infection, Human Immunodeficiency Virus

United Kingdom
Southern Illinois Healthcare Foundation
Janssen Scientific Affairs, LLC

Completed

A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir

HIV-1-infection
ViiV Healthcare

Completed

Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment

HIV Infections | Infection, Human Immunodeficiency Virus

United States
University of California, San Francisco
Merck Sharp & Dohme LLC

Completed

Raltegravir Intensification in HIV-infected Patients

HIV Infections

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy Volunteers

HIV Infections

United States
Haitian Group for the Study of Kaposi's Sarcoma...
Harvard Medical School (HMS and HSDM); Brigham and Women's Hospital; Weill Medical... and other collaborators

Unknown

Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults

Antiretroviral Therapy | HIV-1-infection

Haiti
ViiV Healthcare

Completed

Dolutegravir Pediatric Liquid Formulation Study

HIV Infections

United Kingdom
Makerere University
Infectious Diseases Institute, Uganda

Unknown

Nucleosides And Darunavir/Dolutegravir In Africa (NADIA)

Human Immunodeficiency Virus

Uganda
Federal University of São Paulo
Fundação de Amparo à Pesquisa do Estado de São Paulo; Conselho Nacional de... and other collaborators

Completed

Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure

HIV | Chronic Infection

Brazil
Fundación FLS de Lucha Contra el Sida, las Enfermedades...
Merck Sharp & Dohme LLC

Completed

Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY

HIV

Spain
Federal University of São Paulo
Gilead Sciences

Unknown

HIV Drug Resistance Among Individuals Failing Tenofovir/Lamivudine and Dolutegravir First Line Regimen in Brazil

HIV | Drug | Resistance
University of California, San Diego
Merck Sharp & Dohme LLC; Abbott; California HIV/AIDS Research Program

Completed

Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients

HIV Infections

United States
The HIV Netherlands Australia Thailand Research...
Chulalongkorn University; National Healthcare Group Pte Ltd, Singapore

Completed

Pharmacokinetics of Low Dose Raltegravir

HIV Infections

Thailand
ViiV Healthcare
Janssen, LP

Completed

Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent

HIV Infections

United States
Instituto de Investigación Hospital Universitario...

Unknown

Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.

HIV-1-infection

Spain
University of California, San Francisco
Merck Sharp & Dohme LLC; Gilead Sciences; California HIV/AIDS Research Program

Completed

HIV Persistence and Viral Reservoirs

HIV Infections | HIV

United States
ViiV Healthcare

Completed

Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers

HIV Infections | Infection, Human Immunodeficiency Virus

United States
Nantes University Hospital

Completed

QDISS Stud: QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient (QDISS)

Virus-HIV

France
Gilead Sciences

Completed

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

United States
Haitian Group for the Study of Kaposi's Sarcoma...
Gilead Sciences; Brigham and Women's Hospital; Weill Medical College of Cornell... and other collaborators

Withdrawn

Same-Day Treatment With Genvoya vs. EFV/TDF/3TC

HIV/AIDS
Fondation Ophtalmologique Adolphe de Rothschild

Withdrawn

Evaluation of the Neurological and Psychiatric Adverse Events of Dolutegravir and Bictegravir in Real Life (NEPALE)

HIV+ Patients
Fondation Ophtalmologique Adolphe de Rothschild

Terminated

Evaluation of Neurologic and Psychiatric Adverse Events of Several Antiretroviral Drugs in Real Life Setting (NEPAL)

HIV

France
Hospital Clinic of Barcelona

Completed

Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients (RAL-LT-HIV)

Liver Transplantation | HIV Infections | Antiretroviral Therapy
Fundacion Clinic per a la Recerca Biomédica

Unknown

Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients

HIV-1-infection | Solid Organ Transplant

Spain
Columbia University

Completed

Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana

HIV Infections | Contraceptive Usage | Drug Interaction

Botswana
Germans Trias i Pujol Hospital

Completed

Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine

HIV Infections

Spain
Azienda Ospedaliera Universitaria Senese
Catholic University of the Sacred Heart; Ospedale Policlinico San Martino; Azienda... and other collaborators

Unknown

Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen (DOBINeuro)

HIV-1-infection

Italy
Westat
National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy...

Completed

Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission

HIV Infections

United States, Puerto Rico, Thailand, Argentina, Brazil, South Africa, Tanzania
ViiV Healthcare
GlaxoSmithKline

Completed

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

HIV Infections | Infection, Human Immunodeficiency Virus

United States, Canada
Erasmus Medical Center

Completed

The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial (DOMONO)

Human Immunodeficiency Virus

Netherlands
ADRIANO LAZZARIN, MD
Ministero della Salute, Italy

Unknown

Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI). (P25-INACTION)

HIV-1-infection

Italy
Saskatchewan Health Authority - Regina Area
Gilead Sciences

Unknown

Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy

Hepatitis C, Chronic | HIV/AIDS | Bone Diseases, Metabolic | Opioid Dependence | HIV-1-infection | HCV Coinfection | Buprenorphine Dependence | Methadone Dependence | Co-infection

Canada
Germans Trias i Pujol Hospital
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la...

Completed

Pilot Study to Compare the Pharmacokinetics Parameters in Plasma and Intracellular of Raltegravir Administered Once a Day in Adult Patients Infected With HIV

HIV Infections

Spain
Germans Trias i Pujol Hospital
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la...

Completed

Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy

HIV Infections

Spain

Search clinical trials for: integrase inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations